Dr David Fackrell, Consultant Clinical Oncologist
Dr David Fackrell
Consultant Clinical Oncologist
Dr David Fackrell
Consultant Clinical Oncologist BSc MBChB MRCP FRCR
Dr Fackrell is a Consultant Clinical Oncologist
Areas of expertise
- Bladder cancer treatment
- Chemotherapy (cancer treatment)
- Kidney cancer treatment
- Oesophageal cancer treatment
- Radiotherapy
Make an appointment
Address
-
The Harborne Hospital, part of HCA Healthcare UK
Mindelsohn Way, Birmingham, B15 2TQ
About Dr David Fackrell
GMC number: 6146525
Year qualified: 2006
Place of primary qualification: Leicester Warwick Medical School
Dr David Fackrell is a consultant clinical oncologist specialising in the diagnosis and treatment of prostate cancer and other urological malignancies, practising at the Birmingham Prostate Clinic. He brings extensive expertise in delivering personalised cancer care that integrates state-of-the-art treatment with a patient-centred approach.
He trained in medicine and completed specialist training in clinical oncology, gaining comprehensive experience in systemic cancer therapies, radiotherapy techniques and multidisciplinary cancer management. His clinical practice focuses on prostate cancer care, guiding patients through diagnosis, treatment selection and long-term follow-up with clarity and support.
Dr Fackrell’s areas of expertise include prostate cancer diagnosis and management, active surveillance protocols, hormonal therapies, chemotherapy, immunotherapy and radiotherapy. He works closely with urological surgeons, radiologists, specialist nurses and allied health professionals to coordinate treatment plans that reflect the latest clinical evidence and individual patient goals. His approach emphasises shared decision-making, ensuring patients and their families fully understand their condition and the options available.
In addition to prostate cancer, Dr Fackrell manages a range of urological and related cancers as part of a multidisciplinary team. He is involved in clinical audit, quality improvement and research activities that aim to refine treatment pathways, optimise outcomes and reduce the side effects associated with cancer therapies.
He is known for his compassionate care style, combining clinical expertise with clear communication and empathy. Dr Fackrell supports patients throughout their cancer journey, from initial assessment through treatment and recovery, with a focus on maintaining quality of life and long-term wellbeing.
Areas of expertise
- Bladder cancer treatment
- Brachytherapy
- Chemotherapy (cancer treatment)
- Diagnostics
- Hormone therapy
- IMRT
- Kidney
- Kidney cancer treatment
- Oesophageal cancer treatment
- Oesophagus
- Prostate bladder
- Radiotherapy
- stomach cancer
- Stomach cancer treatment
- Targeted therapy for cancer
- Treatment of urological cancers
- Upper gastrointestinal cancers
Professional memberships
Articles by Dr David Fackrell
Tolerability, toxicity, and outcomes following surgical and non-surgical approaches to the management of patients with locally advanced oesophageal squamous cell carcinoma
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy
Survival benefit of adjuvant chemotherapy following neoadjuvant therapy and oesophagectomy in oesophageal adenocarcinoma
P-OGC35 Does Adjuvant Chemotherapy Provide Additional Survival Benefit AfterNeoadjuvant Chemotherapy or Chemoradiotherapy and Esophagectomy forEsophageal Adenocarcinoma?
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial
Bladder cancer
Radical treatment of muscle-invasive bladder cancer—are options equal?
Evaluating efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer (CRPC) and metastatic bone disease, with or without previous docetaxel use
